The addition of apatinib when the patients got slow progression after initial EGFR-TKI therapy may be a good treatment option and the side effects are controllable. It is possible to monitor treatment efficacy using ctDNA.
Keyphrases
- end stage renal disease
- small cell lung cancer
- tyrosine kinase
- chronic kidney disease
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- epidermal growth factor receptor
- prognostic factors
- advanced non small cell lung cancer
- stem cells
- mesenchymal stem cells
- patient reported outcomes
- chronic myeloid leukemia
- cell therapy